A dear friend has a new gout attack so am looking up the latest in prevention and treatment.
Key points:
1. Gout is an inflammatory arthritis due to deposition of monosodium urate crystals.
2. It is associated with hyperuricemia: aserum urate level of 6.8mg per decilitre (404micromol per liter) or more
3. Approximate US prevalence: estimated at 3.9% of adults (~8.3 million people).
4. Treatments for acute attack include:
A. NSAIDS nonsteroidal anti-inflammatory drugs
B. colchicines: allopurinol is cheap and effective
C. glucocorticoids and possibly corticotrophin: many risks
D. New treatment option:
“Canakinumab is very expensive,” said Solomon. Its main role to date is as a last-ditch treatment for rare, so-called “orphan” diseases. At its current price, he said, “it is not a viable option for most patients with gout.”
Also, it must be injected every three months by a caregiver.
Still, Solomon said Ilaris may have a clinical role for patients who don’t respond to or tolerate standard medications.
Prior research had shown that interleukin-1B inhibitors can shorten gout attacks, but it wasn’t known if they could prevent them, the study authors said.
The new research was funded by Novartis, the maker of Ilaris. The results were published online Sept. 17 in Annals of Internal Medicine.
E. PRP is an emerging treatment but 1 case report of PRP injection making gout attack. for a variety of musculoskeletal disorders involving ligament bone joint and muscles. It had been studied in conditions such as cruciate
When uric acid, the end product of purines metabolism, rises above 6.8 mg/dL in peripheral blood, urate sediments can form within tissues.
https://comportho.com/wellness/injected-drug-may-be-new-weapon-against-gout/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4170825/
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/775622
https://www.medpagetoday.com/rheumatology/generalrheumatology/80325